The following extracts are taken from this perspective published in the Scotsman, 11 January 2018:
Pfizer has seemingly concluded that Alzheimer’s disease is far more complex than we had ever anticipated.
Perhaps this indicates that the 110 year old “paradigmatic pathology” of Alzheimer’s disease does itself need a paradigm shift.
Meantime, the “Edinburgh Consensus” demonstrates limitless faith in the current paradigm, to the extent that they recommend that research criteria should be introduced into the NHS.